TriGenex

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

Bifidobacterium infantis, Quantity: 3.2 billion CFU; Bifidobacterium longum, Quantity: 4.1 billion CFU; Bifidobacterium breve, Quantity: 4 billion CFU

Disponible depuis:

Biomedica Nutraceuticals Pty Ltd

DCI (Dénomination commune internationale):

Bifidobacterium breve,Bifidobacterium infantis,Bifidobacterium longum

forme pharmaceutique:

Capsule, hard

Composition:

Excipient Ingredients: microcrystalline cellulose; colloidal anhydrous silica; tricalcium phosphate; tapioca starch; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum

Mode d'administration:

Oral

indications thérapeutiques:

Maintain/support general health and wellbeing ; Maintain/support healthy digestive system function ; Maintain/support healthy digestion ; Maintain/support digestive system health ; Maintain/support intestinal good/beneficial/friendly flora ; Helps restore good/beneficial/friendly intestinal/gut/bowel flora ; Maintain/support immune system health ; Maintain/support healthy immune system function

Descriptif du produit:

Visual Identification: ;

Statut de autorisation:

Licence status A

Date de l'autorisation:

2017-06-30